Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.74 USD | +2.35% | +10.13% | +13.73% |
May. 02 | Transcript : Lexicon Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Posts Q1 Revenue $1.1M, vs. Street Est of $1.4M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.73% | 428M | C- | ||
+8.96% | 105B | B+ | ||
-1.43% | 104B | B+ | ||
+4.40% | 22.94B | B | ||
-12.15% | 22.34B | B+ | ||
-4.36% | 19.25B | A- | ||
-39.98% | 17.08B | A- | ||
-10.04% | 16.96B | B | ||
+6.79% | 14.16B | C+ | ||
+38.61% | 12.63B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LXRX Stock
- Ratings Lexicon Pharmaceuticals, Inc.